NBIX
NEUROCRINE BIOSCIENCES INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$146.23
−3.69%Next report
Analyst consensus
- Next report date
- Oct 27, 2026
- EPS estimate
- $2.59
- Revenue estimate
- $1.0B
Latest reported
- Last report date
- Jul 30, 2026
- EPS actual
- $1.39
- EPS estimate
- $1.65
- Revenue actual
- $959.0M
- Revenue estimate
- $891.2M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +6.9%
- Revenue beats (12Q)
- 8
Analyst ratings
Sell-side consensus
- Consensus
- Strong Buy
- Price target
- $208
- PT range
- $170 – $253
- Analysts
- 16
14 Buy2 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Jul 30, 2026 | $1.65 | $1.39 | Miss -15.76% | $959.0M |
| May 5, 2026 | $1.28 | $1.94 | Beat 51.56% | $814.5M |
| Feb 11, 2026 | $2.25 | $1.88 | Miss -16.44% | $805.5M |
| Jul 30, 2025 | $0.98 | $1.06 | Beat 8.16% | $687.5M |
| Feb 6, 2025 | $1.62 | $1.00 | Miss -38.27% | $627.7M |
| Oct 30, 2024 | $1.51 | $1.24 | Miss -17.88% | $622.1M |
| Aug 1, 2024 | $1.05 | $0.63 | Miss -40.00% | $590.2M |
| May 1, 2024 | $1.01 | $0.42 | Miss -58.42% | $515.3M |
| Feb 7, 2024 | $1.15 | $1.44 | Beat 25.22% | $515.2M |
| Oct 31, 2023 | $0.97 | $0.82 | Miss -15.46% | $498.8M |
| Aug 1, 2023 | $0.78 | $0.95 | Beat 21.79% | $452.7M |
| May 3, 2023 | $0.26 | -$0.79 | Miss -403.85% | $420.4M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 27, 2026